01What does HPLC purity tell a peptide buyer?
Reversed-phase HPLC commonly estimates the relative area of the target chromatographic peak under a stated method. It helps answer whether UV-detectable related species are separated and how much of the integrated signal belongs to the assigned target peak. The result is method-dependent: column chemistry, gradient, mobile-phase modifier, wavelength, temperature, sample preparation and integration rules can change the reported percentage. Review the chromatogram, target-peak assignment, run window, baseline and method summary when the decision risk justifies it. A high area percentage does not prove molecular identity, absolute peptide content, sterility or absence of non-UV-active material. The acceptance criterion should be selected against the experiment and impurity risk, not treated as a universal quality score. Raw data availability and method transfer expectations must be agreed before quotation.
- Column and mobile-phase method
- Detection wavelength and integration
- Target-peak retention assignment
- Acceptance limit and numerical result
- Chromatogram linked to the supplied lot
Read the peptide purity guide ↗02What does mass spectrometry confirm for a peptide?
Mass spectrometry supports identity by comparing observed ions with the expected molecular mass. Because peptides often produce multiple charge states and adducts, a useful report states the calculated mass, observed mass, ion assignment, tolerance and instrument or method context. A matching molecular ion is important evidence, but it does not independently establish sequence order, stereochemistry, chromatographic purity or concentration. Isobaric substitutions, epimers and co-eluting variants can require higher-resolution or orthogonal characterization. For custom or modified peptides, make sure the calculation includes termini, labels, linkers, salt assumptions and other modifications. The spectrum, report and COA must carry the same product and lot identity. Buyers should request additional confirmation only when the scientific risk warrants it rather than assuming one standard MS package answers every question.
- Calculated molecular mass
- Observed ions and charge states
- Mass tolerance and assignment
- Modification-aware calculation
- Spectrum-to-lot traceability
Review the quality approach ↗03When are peptide content, water and counter-ion tests needed?
These tests become important when the amount of usable peptide or material balance affects the downstream calculation. HPLC area purity normally describes relative chromatographic signal, not how much of the vial mass is target peptide. Lyophilized material may also contain water, TFA, acetate, chloride, salts or excipients. Peptide content can be assigned by an agreed method such as amino-acid analysis, nitrogen analysis, quantitative NMR or another validated approach, depending on the material. Water may be assessed separately, and counter-ion testing can support comparability between lots or formulations. Define whether the purchase quantity is gross material, dry basis or peptide content before ordering. Do not add tests only to make a longer COA; add them when they control a real dosing, formulation, calibration or mass-balance decision in the qualified research workflow.
- Quantity definition used in the PO
- Peptide-content method and basis
- Water method and acceptance limit
- Counter-ion identity and amount
- Calculation used by the receiving lab
Learn how to read a peptide COA ↗04Which additional peptide release tests should be specified?
Additional tests follow intended use, material risk and the buyer's control strategy. Possible attributes include appearance, solubility, residual solvents, elemental impurities, bioburden, endotoxin, water, counter-ion, pH for solutions, or project-specific functional and orthogonal identity methods. Each test needs a defined sample, method, acceptance criterion and reporting format. Endotoxin, bioburden and sterility are not implied by HPLC purity, and one cannot be substituted for another. Likewise, a generic solubility statement does not establish performance at the buyer's target concentration, buffer, pH and temperature. State mandatory release tests in the RFQ and separate them from optional development work. PeptideSum confirms feasibility and inclusion in the written quotation; tests not named in the agreed scope should not be assumed from a catalog description or representative document.
- Intended context and risk question
- Method feasibility and sample amount
- Acceptance criterion
- Release versus information-only status
- COA, raw-data and report format
Request the applicable document package ↗Ask a technical question ↗ 